Im­pel Phar­ma con­sid­ers bank­rupt­cy, as­set sales de­spite mi­graine nasal spray quar­ter­ly rev­enue jump

There is “sub­stan­tial doubt” that Im­pel Phar­ma­ceu­ti­cals can con­tin­ue, and the biotech, which has one mi­graine nasal spray treat­ment, is con­sid­er­ing bank­rupt­cy or sell­ing off …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER